INS and type 2 diabetes mellitus: A pan-PPAR agonist, lanifibranor, is currently being tested in phase II studies, with enabling data showing improved insulin sensitivity in T2D and improved intra-hepatic lipid content in T2D-associated NAFLD (clinicaltrials.gov #NCT03459079).